The Covid crisis is an almost caricatural illustration of how the economics of pharmaceuticals condemns us to inexorably reduce the number of people who have access to health innovations – in poor and rich countries alike. Changing this trajectory, and avoiding the multiplication of sorting on an economic basis, requires a precise understanding of the current dysfunctions, distortions and abuses in order to suggest alternative ways of manufacturing and managing products on which our lives may depend.

What are the symptoms that affect the pharmaceutical economy? What diagnoses can be established on the basis of these manifestations of dysfunction? What could be the treatments for this failing system? A short and concise book that provides solid arguments for a re-invention of the economics of pharmaceuticals.